You know the standard curative treatment for multiple myeloma (MM) includes an allogeneic stem cell transplant. But what about all your older patients who aren’t candidates for such toxic therapy? The interim analysis of ALCYONE trial published this month in NEJM demonstrated that the addition of daratumumab (anti-CD38) to standard multi-agent chemo almost doubled complete response rates (24% -> 42%) and did double rates of progression-free survival. Of note, among 750 patients with a median age of 71 (and at least one feisty 93 year-old), the addition of daratumumab didn’t even increase the overall toxicity rate. TBL: Talk to your older patients with MM about adding daratumumab to their chemo regimens.